Clinical Trial

REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation

Study acronym: REDEL
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated December 18, 2025 (before its estimated August 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-06-05; most recent amendment 2025-12-16.
Status change: Recruiting → Active, Not Recruiting 2025-12-16
Status change: Not Yet Recruiting → Recruiting 2023-08-21
Trial Details
NCT Number NCT05902533
Lead Sponsor University of Cincinnati
Conditions Anal Cancer
Enrollment 33 participants
Start Date 2023-08-14
Primary Completion 2026-08-14 (estimated)
Study Completion 2029-08-14 (estimated)
Updated on ClinicalTrials.gov 2025-12-18